GCIA
CBPO

Gabelli & Co Investment Advisers’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,400
Closed -$352K – 222
2018
Q3 		$352K Buy
+4,400
New +$410K 0.04% 132

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gabelli & Co Investment Advisers's CBPO Position: Q4 2018 in Review

Gabelli & Co Investment Advisers sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2018, closing a stake of 4,400 shares — an estimated $352K sold.

Gabelli & Co Investment Advisers first reported a position in CBPO in Q3 2018 and held it in 1 quarter. The position peaked at $352K in Q3 2018. 67 funds tracked by Wall St. Rank hold CBPO as of Q4 2018.

  • Gabelli & Co Investment Advisers reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 4,400 China Biologic Products Holdings, Inc. shares in Q4 2018, an estimated $352K.
  • Gabelli & Co Investment Advisers first reported a position in China Biologic Products Holdings, Inc. in Q3 2018 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's China Biologic Products Holdings, Inc. position peaked at $352K in Q3 2018.
  • 67 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2018.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2018, filed 30 Jan 2019.